Wagner Florian, Heidtke Karsten R, Drescher Bernd, Radelof Uwe
ATLAS Biolabs GmbH, Friedrichstrasse 147, 10117 Berlin, Germany.
Brief Funct Genomic Proteomic. 2007 Sep;6(3):163-70. doi: 10.1093/bfgp/elm026. Epub 2007 Oct 29.
A number of fundamental technical developments like the evolvement of oligonucleotide microarrays, new sequencing technologies and gene synthesis have considerably changed the character of genomic biological resource centres in recent years. While genomic biological resource centres traditionally served mainly as providers of sparsely characterized cDNA clones and clone sets, there is nowadays a clear tendency towards well-characterized, high-quality clones. In addition, major new service units like microarray services have developed, which are completely independent of clone collections, reflecting the co-evolution of data generation and technology development. The new technologies require an increasingly higher degree of specialization, data integration and quality standards. Altogether, these developments result in spin-offs of highly specialized biotech companies, some of which will take a prominent position in translational medicine.
近年来,诸如寡核苷酸微阵列的发展、新的测序技术和基因合成等一些基础技术进步,极大地改变了基因组生物资源中心的性质。传统上,基因组生物资源中心主要作为特征描述较少的cDNA克隆和克隆集的提供者,而如今明显倾向于特征明确的高质量克隆。此外,像微阵列服务这样的主要新服务部门已经发展起来,它们完全独立于克隆文库,反映了数据生成和技术发展的共同演进。新技术要求越来越高的专业化程度、数据整合和质量标准。总体而言,这些发展催生了高度专业化的生物技术公司的衍生企业,其中一些将在转化医学中占据重要地位。